Quarterly Result29 May 2026, 12:35 am
Beryl Drugs FY26 Audited Results Declared
AI Summary
Beryl Drugs Limited announced its audited financial results for the quarter and year ended March 31, 2026, along with the Independent Auditor's Report. The auditors highlighted a potential unrecorded liability for professional tax due to non-registration. Revenue from operations for FY26 was adversely impacted by a stop manufacturing order for its Blow Fill Seal (BFS) section, effective from February 2025 until its revocation on November 28, 2025. The company also adopted Ind AS 116 - Leases from April 1, 2024, resulting in a ₹30.03 Lakh adjustment to the opening balance of Retained Earnings.
Key Highlights
- Audited financial results for Q4 and full year FY26 released.
- Auditors noted potential unrecorded professional tax liability.
- BFS manufacturing halt impacted FY26 revenue negatively.
- Ind AS 116 adoption adjusted retained earnings by ₹30.03 Lakhs.
Price Impact
More from BERLDRG